anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
HIV is a virus that weakens people's immune systems and can cause AIDS. Antiretroviral therapy (ART) is a treatment for HIV that combines different types of antiretroviral medications, but it must be taken throughout a person's life without missing doses to be effective. When people do miss doses, the HIV virus has an opportunity to develop resistance to the medications, making them less effective in the future. Reports indicate that as many as 50% of children infected with HIV who are living in resource-limited countries regularly miss doses of their ART. This study will test different methods for determining children's rates of adherence to ART medications. This will both define the exact magnitude of the problem and direct future efforts in increasing ART adherence in children.

Participation in this study will last 12 months. All children enrolled will undergo a series of assessments of medication adherence. At baseline and every month over the course of the study, researchers will make unannounced home visits to measure the amount of medicine that remains untaken by participants and to record how many times the electronic cap on participants' medication bottles have been removed. Participants with cell phones will also receive monthly phone calls during which they will be asked to measure the amount of their medicine that remains untaken. At study entry and after 6 and 12 months, researchers will also examine child participants' medical records and the results of their regularly scheduled blood tests. At these blood tests, an additional half teaspoon of blood, which may be used in future testing, will be collected and stored by the researchers. After 3, 6, 9, and 12 months, researchers will request to collect hair samples from child participants to test levels of HIV medications in the hair, but participation in this part of the study is optional.

Assessments of reasons for medication adherence will also be performed. At study entry and after 3, 6, 9, and 12 months, children and their parents will complete questionnaires about their understanding of HIV medicines and HIV infection, motivation for the child to take medications, behaviors related to taking medications, and basic personal information. One and 7 months after study entry, some parent participants will also complete interviews with study staff about giving HIV medicines to their children.
There are described trifluoromethylketone derivatives of the following formula: (see formula I) wherein R1 is lower alkyl which has one or two substituents selected from carboxy, esterified carboxy and di-lower alkylcarbamoyl; phenyl(lower)alkyl, the phenyl moiety of which may have halogen or nitro or amino and the alkyl moiety of which may have carboxy or esterified carboxy; halo-phenyl; morpholino; or morpholino(lower)alkyl, R2 and R3 are each lower alkyl, X is - or -NH-, and Y is (see formula II) or (see formula III)~~~ and pharmaceutically acceptable salts thereof. These derivatives have a human leukocyte elastase-inhibiting activity and are useful as human leukocyte elastase inhibitors for treating or preventing degenerative diseases, for example, pulmonary emphysema, atherosclerosis, rheumatoid arthritis, arthrosclerosis, osteoarthritis, psoriasis, pancreatitis, periodontosis, pulmonary fibrosis. Cystic fibrosis, chronic bronchitis, bronchiectasia, diffuse panbronchiolitis, respiratory injury, adult respiratory distress syndrome and the like. They are also useful for the treatment or prevention of asthma, graft rejection nephritis, hydroa, disseminated intravascular coagulation, shock, systemic lupus erythematosus, clone disease, ischemia-reperfusion injury, chronic obstructive pulmonary disease (COPD), premature rupture of the membrane (PROM), corneal sarring or fibroblast proliferation (ocular coagulation, burns, mechanical and chemical injury, kerato-conjunctivitis, etc.), and sepsis. The preparation of these derivatives is also disclosed as well as pharmaceutical compositions containing them, and their use in the above treatments.
Subjects with type II diabetes who follow treatment sequence B-C-A. Single oral dose of 1 mg BAY1193397 in the first intervention period (Treatment B); followed by single oral dose of 5 mg BAY1193397 IR tablet under fasted state in the second intervention period (Treatment C), then single oral dose of a placebo tablet under fasted conditions in the third intervention period (Treatment A). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
PROBLEM TO BE SOLVED: To provide a functionalized biocompatible nanoparticle capable of penetrating through a mammalian cell membrane and delivering intracellularly a plurality of bioactive molecules for modulating a cellular function.SOLUTION: According to the present invention, a functionalized biocompatible nanoparticle comprises: a central nanoparticle ranging in size from 5 to 50 nm and having a polymer coating thereon; and a plurality of functional groups covalently attached to the polymer coating. Here, the plurality of bioactive molecules is attached to the plurality of functional groups. The plurality of bioactive molecules includes at least a peptide and a protein. The peptide is capable of penetrating through the mammalian cell membrane and entering into the cell. The protein is capable of providing a new functionality within the cell. The protein may be a transcription factor selected from the group consisting of Oct4, Sox2, Nanog, Lin28, cMyc, and Klf4.SELECTED DRAWING: None
This is a clinical, randomized, placebo-controlled, crossover and triple-blind study. Ten participants with injury history (stroke) will perform the protocol. The intervention will be held once a week for 4 weeks. Each week a different dose of phototherapy (Placebo, 10J, 30J and 50J) will be applied. The phototherapy, active or placebo, will be applied in 9 different points of anterior muscle of the thigh, 6 different points of posterior muscle of the thigh and 2 different points of the gastrocnemius muscle, bilaterally, before the tests. Only one investigator, that will not participat in any phase of the assessments sessions, will know about what program is active or placebo in phototherapy device. Randomisation will occur by a simple drawing of lots (A, B, C, or D) in the first visit. The phototherapy unit emitted the same sound regardless of the program used, active or placebo. For three-dimensional gait assessment and muscle activity will be used a SMART-D system 140® - BTS Engineering with six cameras, two Kistler force platforms Platform model 9286BA and FREEEMG® electromyography - BTS Engineering wireless system with four channels. In addition, the evaluation will quantify the static balance (force platform), the functional balance (Berg Balance Scale) and mobility (6 minute walk test and go upand team test).
The investigators will use existing data from two US longitudinal birth cohorts that tracked mother-child dyads from pregnancy to adolescence: 1) Project Viva (1999-present) that enrolled 2,341 pregnancies and followed 2,128 children at delivery, 6 months, then yearly from 1 year to 15 years of child age, and 2) the Infant Feeding Practices Study II (IFPS II, 2005-2007) that enrolled 3,033 pregnancies with surveys in late pregnancy, neonatal (1 month), then monthly from 2 months (N=2,552) to 12 months of infant age, and at 6 years. For Aim 1, the investigators will classify infants based on their age of egg introduction: never, \<2 months, 2-3 months, 4-5 months, 6-8 months, 9-11 months, and 12 months. The investigators will compare physical growth, obesity, cardio-metabolic health, food allergy, and cognition test scores in mid-childhood and adolescence. The investigators will fit multi-variable linear or logistic regression models with fractional polynomial functions of the infant age of egg introduction. Both linear (e.g., earlier introduction, a higher probability of the outcome) and non-linear (e.g., threshold effect) associations will be tested. For Aim 2, The investigators will classify infants based on their frequency of egg intake: never, \<once/week, once/week, 2-4 times/week, nearly daily or daily, and 2 times/day. The investigators will use similar analytic methods mentioned above to compare their later outcomes. Finally, the investigators will create an average probability of multiple child outcomes to balance across different aspects of child health and development. The investigators will identify the lowest-risk infant egg consumption when the corresponding average predicted probability of the related adverse outcomes is the lowest.
Subjects will receive 3 SC administrations of the same dose level of JNJ-56022473 or placebo every 2 weeks (in the ratio of 5:1 \[5 active: 1 placebo\]). The dose level(s) will be based upon an interim analysis (IA) of the Part A data.
The invention provides an herbal extracted with active anti-Enterovirus and the preparation of same, mainly composed of the rootstalks or the compound of polygonum cuspidatum Sieb. et Zucc. or rhubarb (Rheum palmatum L.; R. officinale Baill.; R. tanguticum Maxim. ex Balf.), extracted with at least one solvent. The extract of polygonum cuspidatum Sieb. et Zucc. or rhubarb with at least the compound from the following chemical formula. The invention also includes the extract of polygonum cuspidatum Sieb. et Zucc. or rhubarb or composite medication compound from the aforementioned chemical formula, which effectively resists enterovirus activity and provides clinical medical prevention or treatment of enterovirus.
The invention discloses a p-benzene ring butanamide rosemary compound, a preparation method thereof and application thereof as a hyaluronidase inhibitor and in preparing anti-aging cosmetic products. Specifically, the invention discloses a series of preparation of rosmarinic acid derivatives. The in vitro activity test shows that the rosmarinic acid derivative has stronger hyaluronidase inhibition activity, IC  50  About 10-20 μ g/mL, the inhibitory activity is obviously higher than that of rosmarinic acid and IC  50  About 102. Mu.g/mL. The rosmarinic acid derivative has very low cytotoxicity, has obviously enhanced fat solubility compared with rosmarinic acid, is easier to be absorbed by skin tissues, and can be used as an anti-aging component for preparing a cosmetic product. The invention also discloses an application of the rosmarinic acid derivative as a cosmetic component in preparing an anti-skin-aging facial mask.
High-dose cyclophosphamide at 2.0 g/m2 on day 1. G-CSF is given for ten (+/- two) consecutive days starting on day 2 at a dose of 10 micrograms/kg/day. Pheresis will commence once ANC of 1.5 is reached.
Diagnostic evaluation of a patient with dizziness or vertigo is complicated by a lack of standardized nomenclature, significant overlap in symptom descriptions, and the subjective nature of the patient's symptoms. Although dizziness is an imprecise term often used by patients to describe a feeling of being off-balance, in many cases dizziness can be subcategorized based on symptomatology as vertigo (false sense of motion or spinning), disequilibrium (imbalance with gait instability), presyncope (nearly fainting or blacking out), or lightheadedness (nonspecific). As such, current diagnostic paradigms focus on timing, triggers, and associated symptoms rather than subjective descriptions of dizziness type. Regardless, these factors complicate the selection of appropriate diagnostic imaging in patients presenting with dizziness or vertigo. This document serves to aid providers in this selection by using a framework of definable clinical variants. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.
HIV infection can result in memory and thinking difficulties in some people, even those successfully treated with antiretroviral medications. Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV. Abdominal fat accumulation is linked to memory and thinking difficulties, and previous studies have suggested that tesamorelin also may be beneficial for memory and thinking, but this has not been tested in HIV. The aim of this study is to test whether tesamorelin, in combination with a text-messaging application to help with motivation and adherence, will significantly improve memory and thinking in HIV. We plan to enroll 100 volunteers with HIV infection at 2 sites - the University of California, San Diego and the University of Southern California, University of San Francisco and the satellite site, PalmTree Clinical Research, Inc. Before entry, volunteers will be required to show evidence of abdominal obesity and a minimum level of memory and thinking difficulties on cognitive tests. This is a randomized trial in which each volunteer will have a 60% chance of initially receiving tesamorelin (the immediate group) and a 40% chance of initially receiving no treatment (the deferred group). Subsequently, the deferred group (those who initially received no treatment) will receive tesamorelin for 6 months and those who initially received tesamorelin will receive no treatment for 6 months. Volunteers will be trained in the use of a 2-way text-messaging system that will help the research team to support volunteers' ability to take the study medication as directed. We will measure volunteers' memory and thinking skills before and at the end of treatment. We will collect blood at various points during the study to check for safety of the treatment and to determine its effects on the body. Volunteers will also be asked to have magnetic resonance scans of the head and abdomen to monitor the effects of the study medication on brain chemistry and abdominal fat.
A bolus for administering a biologically active material for example an insecticide into a liquid environment such as the water of a reservoir or lake or an anthelmintic into the rumen juices of an animal comprises a succession of liquid impermeable outer segments (153, 263) enclosing a core which in the simplest case may be a single unitary active material segment (151, FIG. 14) or in a developed embodiment may comprise a succession of annular segments (269, FIG. 25) contained in sealed recesses (267) in the outer segments (263) which are located on a degradable central rod (265) e.g. of magnesium alloy, which itself will be active for instance to combat magnesium deficiency. 
     As shown in FIG. 25, the device may incorporate a weight (275) which, in animal use, inhibits regurgitation. Additionally, the device may include a galvanic couple element which, with the rod (265) sets up a galvanic action which controls the speed of degradation of the rod (265) and thereby the rate of administration of the segments (26).
Patients will be treated with daily medication prescribed by the physician. Additionally, patients will receive 6 sessions (2 times a week during 3 weeks) of Pulmonary Rehabilitation (PR). PR will include breathing retraining and airway clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training, education and psychosocial support.
Disclosed is a composition for inhibiting oral pathogens. The composition comprises an effective amount of Bacillus subtilis (Bacillus subtilis subsp. Subtilis, BS139), and a diluent, exipient or carrier. By antibiotics of short peptides secreted from Bacillus subtilis, the pathogen, particularly Streptoccocus mutans can be inhibited. The Bacillus subtilis strain used herein is the strain deposited in Bioresource Collection and Research Center (BCRC910457). Otherwise, the foregoing composition also can be used for a method of inhibiting oral pathogens.
Transcutaneous spinal cord stimulation (tSCS) is becoming a promising neuromodulation technique to promote motor recovery in various neurological conditions, including stroke. As this intervention moves forward into clinical practice, it is important to understand how the elicited neurophysiological measures are related to the functional and neuromuscular deficits of the population of interest in order to personalize tSCS interventions and assess its effectiveness. Specifically, neurophysiological measurements of spinal cord excitability can be achieved by recording with EMG spinal motor evoked responses (sMERs) in muscles after applying single pulses of tSCS to the spinal cord. The objective of this study was to investigate potential correlations between baseline spinal cord excitability, as measured by resting motor threshold (RMT) and peak-to-peak (P2P) amplitude of the sMERs, and various factors including demographic characteristics, severity of spasticity, muscle strength, and gait speed in individuals post-stroke. Additionally, the study sought to explore disparities in excitability between the paretic and non-paretic sides. Fifteen participants with chronic stroke underwent sMER assessments. We observed a strong positive correlation between RMT and body weight, indicating weight as a potential confounding variable when comparing RMTs from sMERs between individuals. Furthermore, paretic muscles exhibited lower RMTs and higher P2P amplitudes compared to non-paretic muscles. The results demonstrate that sMERs hold promise in uncovering disparities in spinal excitability in stroke participants. Furthermore, careful interpretation and analysis of sMERs is advised, particularly as higher RMTs were associated with higher body weight and could impact the clinical feasibility of tSCS for some participants. These results should be considered in future tSCS protocols that aim to develop more personalized interventions across different neurological populations and optimize sMERs' utility as an outcome measure.
This invention relates to modulating cellular apoptosis in an animal by regulating the quantity of functional KILLER/DR5 receptor protein molecules in the target cell(s) of said animal, increasing the effectiveness of certain therapies such as chemotherapy and radiotherapy. Such modulation increases the difference in toxicity response between target cell(s) and non-target cell(s) in response to a therapy or treatment and comprises upregulation of wild-type proteins in cells targeted for increased apoptosis or upregulation of loss-of-function proteins in cells targeted for decreased apoptosis. The methods of this invention comprise administering a nucleic acid sequence encoding a wild-type KILLER/DR5 receptor protein or a nucleic acid sequence encoding a loss-of-function mutant KILLER/DR5 receptor protein to said animal. The pharmaceutical compositions of this invention comprise a loss-of-function KILLER/DR5 receptor protein. The isolated nucleic acid sequences of this invention comprise wild-type KILLER/DR5 receptor nucleic acid sequence(s) bearing one or more point mutations at selected amino acid(s). A target of this invention is spleen and gastrointestinal cancer cells.
Patients will be imaged with the Vivascope 1500m multiwavelength coherence microscope during a single patient visit. The lesion will be photographed with high resolution photography and surface epiluminescence microscopy. The clinically uninvolved site will be imaged in the same manner.

The lesion will then be prepped for RCM imaging. A skin contact device consisting of a metal ring and template will be applied to the skin surrounding the lesion of interest with a disposable medicalgrade adhesive plastic disc. A wetting solution will be placed into the metal ring. The wetting solutions include water, mineral oil and other over the counter products (e.g. hairstyling gel and moisturizing agents). Application of these agents diminishes artifacts caused by light scattering at the skin surface. RCM images of the lesion will be captured through the contact device using the Vivascope 1500m surface confocal microscope provided by Lucid Technologies, Inc. Two types of images will be collected, VivaBlocks and VivaStacks. VivaBlocks are a 4x4 mosaic of confocal images that measure 2mm x 2mm in total area. These VivaBlock images are optically combined or "stitched" together by the VivaScope 1500m to create a seamless representation of 4 mm 2 area at a specific depth within the skin. VivaStacks are eight 0.5mm x 0.5mm confocal images taken at 3 micron intervals from the keratin layer to the superficial dermis. VivaStacks and VivaBlocks will be acquired for both the skin lesion and for the clinically uninvolved area of the skin. The total estimated imaging time for a patient in this study is about 30 minutes for the lesion and the clinically uninvolved site.

The confocal imaging session and the dermatologic visit for the punch biopsy do not have to occur during the same patient visit. All lesion images will be saved on a network server for later review and analysis. All imaging will be completed by trained research staff familiar with confocal imaging.
PURPOSE: To obtain a water-based composition enhanced in antimicrobial activities and useful for dentifrice, therapeutic agents for pyrorrhea alveolaris, etc., by blending a specific compound to hinokitiol having antimicrobial activities, a wide antibacterial spectrum and little stimulation against the skin. CONSTITUTION: In this water-based composition, hinokitiol or its salt (0.001-1w/w% is preferable) is mixed with urea (0.1-20w/w%). By mixing urea with hinokitiol or its salt, antimicrobial activity of hinokitiol can be greatly enhanced. By using the water-based composition as cosmetics, contamination of microorganism can be prevented and skin cleanness can be maintained. When used as hair cosmetics such as shampoos, dnadruff preventing effects can be obtained. When used as a hair raising material, hair raising effect can be improved.
The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise promoters active to promote expression specific to cell types or tissues. Further, promoters are providing that are amenable to control by activators, enhancers, or repressors These vectors are in a self-inactivating configuration for biosaftey. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element, without any decrease in the specificity or control exerted by the promoters. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the.study of hematopoiesis via lentivector-mediated modification of human HSCs.